bullish
AptaBio Therapeutics (293780 KS): Promising, Innovative, and First-In-Class Pipeline
331 Views05 Nov 2021 17:50
SUMMARY
- AptaBio Therapeutics (293780 KS) shares surged 28% in last one month, increasing its one-year gain to 213% versus KOSPI’s gain of 26%. Share price was driven by presentation of clinical progress of AptaBio’s pipeline at a virtual meeting held from October 7 to 9, 2021.
- By leveraging on its two proprietary platform technologies, NOX inhibitor discovery platform and Aptamer-drug conjugate platform, AptaBio has developed eight new clinical candidates for complications of diabetes mellitus and three new candidates for anticancer agents. Its lead candidate APX-115 is also being studied as an oral COVID-19 treatment.
- This insight has analyzed the strength and potential of AptaBio’s late-stage pipeline to find whether further stream is left after a spectacular rally in share price in last one year.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- AptaBio Therapeutics (293780 KS): Near-Term Cash Crunch Is Clouding Promising Prospects of Pipeline22 Sep 2022
- AptaBio Therapeutics (293780 KS): Promising, Innovative, and First-In-Class Pipeline05 Nov 2021
x